Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Expert Profile
Views:
129
Share
QR code
Edit Profile
Roberto Firpi-Morell
Professor
MD-GASTROENTERLOGY-LIVER | COLLEGE-MEDICINE
View:
Select
All (all in one)
Research Terms and Keywords
Publications
Network
Websites
Contact
All
Research
Publications
Network
Websites
Contact
Research Terms & Keywords
Research Terms
Medical Sciences
Industries
Health Care
Research Projects
Ends
Title
04-2026
Reducing tobacco-associated lung cancer risk: A randomized clinical trial of AB-free kava
Reducing tobacco-associated lung cancer risk: A randomized clinical trial of AB-free kava
FL DEPT OF HLTH BIOMED RES PGM/J&E KIN
08-2023
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects
NATL INST OF HLTH NCCA
12-2022
A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"
A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"
INTERCEPT PHARMACEUTICAL
12-2022
A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"
A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"
SYNEOS HEALTH
08-2022
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
INC RESEARCH IN
08-2022
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
INTERCEPT PHARMACEUTICAL
07-2021
An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
ABBVIE
04-2021
Merck MK5172-017 "A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/orViral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have BeenPreviously Treated with MK-5172 in a Prior Clinical Trial"
Merck MK5172-017 "A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/orViral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have BeenPreviously Treated with MK-5172 in a Prior Clinical Trial"
Merck Sharp & Dohme
06-2020
AASLD 2019 NP/PA CLINICAL HEP0ATOLOGY FELLOWSHIP PROGRAM
AASLD 2019 NP/PA CLINICAL HEP0ATOLOGY FELLOWSHIP PROGRAM
AMER ASSO FOR STUDY OF LIVER DISEAS
04-2019
Conatus IDN-6556-07 A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had HCV Reinfection & Liver Fibrosis following Orthotopic Liver Transplantation for HCV Infection & Who Subsequently Achieved a SVR Following anti-HCV Therapy
Conatus IDN-6556-07 A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had HCV Reinfection & Liver Fibrosis following Orthotopic Liver Transplantation for HCV Infection & Who Subsequently Achieved a SVR Following anti-HCV Therapy
SC LIVER RESEARCH CONSORTIU
03-2019
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection
Merck Sharp & Dohme
10-2018
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.
MERCK SHARP & DOHME CORP
09-2017
BMSAI444-026 "An Open-Label Re-treatment Study with Peg-Interferon alfa-2a, Ribavirin and BMS-790052 With or Without BMS650032 for Subjects with Chronic Hepatitis C"
BMSAI444-026 "An Open-Label Re-treatment Study with Peg-Interferon alfa-2a, Ribavirin and BMS-790052 With or Without BMS650032 for Subjects with Chronic Hepatitis C"
BRISTOL MYERS SQUIBB C
09-2017
"AbbVie M14-490" An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic HCV Infection and Cirrhosis (TURQUOISE-III)
"AbbVie M14-490" An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic HCV Infection and Cirrhosis (TURQUOISE-III)
ABBVIE
09-2017
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
ABBOTT LABORATORIE
09-2017
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
ABBVIE
06-2017
'MK5172-060: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Na?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection.
'MK5172-060: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Na?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection.
Merck Sharp & Dohme
06-2017
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis
GILEAD SCIENCE
04-2017
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who Failed Prior Tx with Peg/RBV with HCV GT1, GT4, GT5, and GT6
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who Failed Prior Tx with Peg/RBV with HCV GT1, GT4, GT5, and GT6
Merck Sharp & Dohme
04-2017
'MK5172-059 A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV Infection with Advanced Cirrhosisand Child-Pugh (CP)-B Hepatic Insufficiency'
'MK5172-059 A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV Infection with Advanced Cirrhosisand Child-Pugh (CP)-B Hepatic Insufficiency'
Merck Sharp & Dohme
08-2016
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
BRISTOL MYERS SQUIBB C
03-2016
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
ABBOTT LABORATORIE
01-2016
A Phase 2 open-label study in patients with recurrent Genotype 1 hepAtitis C post-orthotopic Liver transplAnt to eXplore the safety and efficacY of simeprevir and sofosbuvir with and without ribavirin
A Phase 2 open-label study in patients with recurrent Genotype 1 hepAtitis C post-orthotopic Liver transplAnt to eXplore the safety and efficacY of simeprevir and sofosbuvir with and without ribavirin
JANSSEN RESEARCH & DEVELOPMENT
10-2015
Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
ABBVIE
09-2015
GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
GILEAD SCIENCE
06-2015
BMS AI447-028
BMS AI447-028
BRISTOL MYERS SQUIBB C
10-2014
P2938-0721 QUANTUM
P2938-0721 QUANTUM
PHARMASSE
04-2014
P7977-0724 ATOMIC
P7977-0724 ATOMIC
QUINTILES IN
01-2014
COLO400A2430
COLO400A2430
NOVARTIS PHARMACEUTICALS COR
02-2013
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
PHARMASSE
04-2012
FISSION: P7977-1231
FISSION: P7977-1231
QUINTILES IN
01-2012
RNDMZ OPN-LBL COMPAR EVAL OF CONVERSION FROM CALCINEURIN
RNDMZ OPN-LBL COMPAR EVAL OF CONVERSION FROM CALCINEURIN
AMER HOME PRODS WYETH AYERST RESEARC
01-2011
Debio 025-HCV-207
Debio 025-HCV-207
DEBIOPHARM S
08-2009
FibroScan
FibroScan
ECHOSEN
12-2008
Cyclosporine in Hep C Infection Viral Clearance
Cyclosporine in Hep C Infection Viral Clearance
NOVARTIS PHARMACEUTICALS COR
07-2008
Comparison of PEG-Intron 1.5ug/kg/wk Plus REBETOL vs PEG
Comparison of PEG-Intron 1.5ug/kg/wk Plus REBETOL vs PEG
SCHERING PLOUGH RES INS
Publications
OpenAlex
Search Engines
Last updated on 2/2/25. See our
OpenAlex FAQ
for more about this data.
Search Google Scholar for Roberto Firpi-Morell
OpenAlex Works Search
Co-Investigator Network
David Nelson
Senior Vice President For Health Affairs, Uf & President, Uf Health
University of Florida
Ha-Executive, Office Of Health Affairs
nelsodr@ufl.edu
Inactive Expert
Giuseppe Morelli
Clinical Professor
University of Florida
Md-Gastroenterlogy-Liver, College-Medicine
Inactive Expert
Peggy Parnell
Program Assistant
University of Florida
Md-Gastroenterlogy-Liver, College-Medicine
Virginia Clark
Program Director & Associate Professor
University of Florida
Md-Gastroenterlogy-Liver, College-Medicine
clarkvc@medicine.ufl.edu
Ramzi Salloum
Professor and Division Chief, Implementation Science
University of Florida
Md-Hobi-General, College-Medicine
rsalloum@ufl.edu
Michael Weaver
Professor
University of Florida
Nr-Bns-Biobehavorial Nur Sci, College-Nursing
michael.weaver@ufl.edu
Tuo Lin
Research Assistant Professor
University of Florida
Phhp-Com Biostatistics, Phhp-Com Integrated Programs
tuolin@ufl.edu
Carol Mathews
Donald R Dizney Chair and Professor, Department Of Psychiatry
University of Florida
Md-Psychiatry, College-Medicine
carolmathews@ufl.edu
Chengguo Xing
Professor and Associate Chair
University of Florida
Ph-Medicinal Chemistry, College-Pharmacy
chengguoxing@ufl.edu
Inactive Expert
Zhiguang Huo
Ast Prof
University of Florida
Phhp-Com Biostatistics, Phhp-Com Integrated Programs
Abhisheak Sharma
Director and Assistant Professor
University of Florida
Ph-Pharmaceutics, College-Pharmacy
asharma1@ufl.edu
John Malaty
Professor & Medical Director
University of Florida
Md-Family Med Center at Main, College-Medicine
malaty@ufl.edu
Frank Orlando
Associate Professor & Medical Director
University of Florida
Md-Chfm Springhill, College-Medicine
forlando@ufl.edu
Expertnet Author Network
Experts within Florida Expertnet that have co-authored works with Roberto Firpi-Morell.
Peter Draganov
Professor Of Medicine
University of Florida
Md-Gastroenterology, College-Medicine
pvdragan@ufl.edu
Works Co-Authored: 573
Inactive Expert
Giuseppe Morelli
Clinical Professor
University of Florida
Md-Gastroenterlogy-Liver, College-Medicine
Works Co-Authored: 44
Roniel Cabrera
Medical Director Of Liver Transplant, Section Chief Of Hepatology & Professor
University of Florida
Md-Gastroenterlogy-Liver, College-Medicine
rcabrera@ufl.edu
Works Co-Authored: 61
Virginia Clark
Program Director & Associate Professor
University of Florida
Md-Gastroenterlogy-Liver, College-Medicine
clarkvc@medicine.ufl.edu
Works Co-Authored: 102
Demetra Christou
Associate Professor
University of Florida
Hh-Apk-Administration, College-Hlth/Human Performance
ddchristou@hhp.ufl.edu
Works Co-Authored: 101
Long Dang
Md
University of Florida
Ph-Medicinal Chemistry, College-Pharmacy
danglh@ufl.edu
Works Co-Authored: 49
Steven Hughes
Edward M. Copeland, III Md Professor and Chief, Surgical Oncology
University of Florida
Md-Surgery-Surgonc-Pbs, College-Medicine
steven.hughes@surgery.ufl.edu
Works Co-Authored: 404
Kenneth Cusi
Professor Of Medicine
University of Florida
Md-Endocrinology, College-Medicine
kcusi@ufl.edu
Works Co-Authored: 334
Ramzi Salloum
Professor and Division Chief, Implementation Science
University of Florida
Md-Hobi-General, College-Medicine
rsalloum@ufl.edu
Works Co-Authored: 287
Mustafa Ahmed
Professor Of Medicine
University of Florida
Md-Cardiology, College-Medicine
mustafa.ahmed@medicine.ufl.edu
Works Co-Authored: 112
Chengguo Xing
Professor and Associate Chair
University of Florida
Ph-Medicinal Chemistry, College-Pharmacy
chengguoxing@ufl.edu
Works Co-Authored: 156
Carla Fisher
Professor
University of Florida
Md-Hobi-General, College-Medicine
carlalfisher@ufl.edu
Works Co-Authored: 111
Inactive Expert
Zhiguang Huo
Ast Prof
University of Florida
Phhp-Com Biostatistics, Phhp-Com Integrated Programs
Works Co-Authored: 96
Inactive Expert
Xiuli Liu
University of Florida
Md-Gastroenterology, College-Medicine
Works Co-Authored: 31
Juan Vilaro
Associate Professor, Cardiovascular Medicine; Medical Director Of Heart Transplant
University of Florida
Md-Cardiology, College-Medicine
juan.vilaro@medicine.ufl.edu
Works Co-Authored: 104
John Malaty
Professor & Medical Director
University of Florida
Md-Family Med Center at Main, College-Medicine
malaty@ufl.edu
Works Co-Authored: 47
Frank Orlando
Associate Professor & Medical Director
University of Florida
Md-Chfm Springhill, College-Medicine
forlando@ufl.edu
Works Co-Authored: 33
Inactive Expert
Mohammad Al-Ani
Clinical Assistant Professor
University of Florida
Md-Cardiology, College-Medicine
Works Co-Authored: 95
Inactive Expert
Kalyan Bhamidimarri
University of Miami
Medicine, Medicine
Works Co-Authored: 15
Websites
OpenAlex Works Search
Search Google Scholar for Roberto Firpi-Morell
Contact Information
roberto.firpi@medicine.ufl.edu
3522739477
PO Box 100214 GAINESVILLE, FL 32610-0214
Profile QR code
What is this?
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
